Revolutionizing Lung Cancer Detection: The Role of AI-Derived CAD Software

By Staff Writer

July 12, 2023

Artificial Intelligence (AI)-derived computer-aided detection (CAD) software may be a game-changer in the field of lung cancer screening. These technologies can potentially enhance the detection and measurement of lung nodules in CT scan images, making them a cost-effective solution. However, more evidence is needed to ascertain which technologies are the most clinically and cost-effective.

There is little clinical-effectiveness evidence available on any of the individual technologies which means that more research is needed to fully understand the potential benefits and drawbacks of these technologies. For example, the software could potentially identify more people with benign lung nodules, leading to unnecessary anxiety and CT surveillance. 

Despite these uncertainties, the potential benefits of AI-derived CAD software cannot be ignored. Not only can it potentially increase the detection of lung nodules, but it can also improve reporting of nodule characteristics, assess the growth of lung nodules, and reduce the time to review and report CT scans. 

NICE encourages centres using AI-derived CAD software as part of targeted lung cancer screening to continue generating evidence and sharing their findings. This will help to realise the full potential of these technologies and facilitate comparisons between different software.

Recommendations for further research on the effect of using the software on clinical decision making and the effect of using the software on scan review and reporting time, are listed in the guideline.

Reference url

Recent Posts

ivonescimab clinical trials
Clinical trials Global Keytruda Oncology and cancer research 

Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaboration with Pfizer

Rene Pretorius

🚀 Exciting news in the fight against cancer!

Summit Therapeutics has announced a groundbreaking collaboration with Pfizer to launch clinical trials for ivonescimab, an innovative PD-1/VEGF bispecific antibody. This partnership aims to evaluate the safety and effectiveness of ivonescimab in combination with Pfizer’s antibody drug conjugates across various solid tumors, including non-small cell lung cancer. 🌟

To learn more about this promising development and its potential impact on oncology treatment, dive into the full article!

#SyenzaNews #oncology #clinicaltrials #innovation

ACS Management Innovations
Cardiovascular and metabolic diseases Clinical guidelines and protocols Clinical Practice Data Analysis Diseases Health Equity and Access to Care Health Policy Innovative medicines and medical devices Innovative Tech North America Real-world evidence 

ACS Management Innovations: Transforming Patient Outcomes in Acute Coronary Syndromes

João L. Carapinha

🚀 Are you ready to elevate your understanding of Acute Coronary Syndromes management?

The new 2025 ACC/AHA Guidelines bring cutting-edge innovations, from enhanced antiplatelet therapies to optimized PCI techniques, aiming to dramatically improve patient outcomes and reduce complications. Jump into how these strategies not only enhance immediate care but also pave the way for long-term wellness.

Explore the full article to understand what these advancements mean for patient safety and care quality!

#SyenzaNews #HealthcareInnovation #futureofhealthcare #innovation

Global Childhood Cancer Access
Global Health Policy Healthcare access Oncology and cancer research Paediatrics Sub-Saharan Africa 

Global Childhood Cancer Access

Crystal Lubbe

🌍 What if no child had to face cancer without access to treatment?

The World Health Organization and St. Jude Children’s Research Hospital are addressing the global disparities in childhood cancer care with the launch of the Global Childhood Cancer Access initiative. This program aims to deliver essential medicines to low- and middle-income countries, starting with pilot distributions in Mongolia and Uzbekistan. Future shipments are planned for Ecuador, Jordan, Nepal, and Zambia. Join us in exploring how this collaborative effort is set to transform the landscape of pediatric oncology and improve survival rates.

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER




SERVICES

QUICK LINKS

LINKEDIN
TWITTER
© 2025 Syenza™. All rights reserved.
Made with by Frogiez
schedule a meeting